GR-dependent transcriptional reporter response
Cell-based study · Human pulmonary A549 cells stably expressing a 2×GRE luciferase reporter [1]
Dexamethasone increased reporter activity; antagonist displacement and GR-specific siRNA supported GR dependence. The EC50 is a cellular transcription endpoint.
| Endpoint | Reported result | Reference |
|---|---|---|
| Dexamethasone-induced 2×GRE luciferase activity | EC50 34 nM | [1] |
| Reporter response with GR antagonism or knockdown | Qualitative control result ORG34517 caused rightward parallel concentration-response displacement; GR siRNA strongly attenuated reporter activity, whereas lamin siRNA did not. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration–response series; 1 µM dexamethasone reference response
- Exposure duration
- 6 h dexamethasone exposure
- Method
- Luciferase assay; ORG34517 pretreatment or GR/lamin siRNA controls
- Vehicle
- Dexamethasone dissolved in HBSS; ORG34517 in DMSO (final DMSO <0.1%)
- Co-treatment
- ORG34517: 30 min pretreatment; GR or lamin control siRNA: 24 h before dexamethasone
- Reported limits
- Sigma catalogue number, chemical purity and explicit salt/ester form not specified.
Methods and source locations
Compound reported in the paper: Dexamethasone; Compound label in the paper: Dex
Published compound-level evidence; tested supplier material differs from Adooq A10299. No lot equivalence or salt conversion is established.
Figure 3A–C, caption and Results: Repression of IL-1β-induced Gene Expression by Dexamethasone is Dependent on GR
Dexamethasone-induced 2×GRE luciferase activity: Luciferase; n=4–5, means ± SE in Figure 3A — Figure 3A and accompanying GR-dependence Results
Reporter response with GR antagonism or knockdown: Luciferase; Figure 3A,C n=4–5, means ± SE; Figure 3B immunoblot controls n=5 — Figure 3A–C and accompanying text